Oestrogen and selective oestrogen receptor modulators (SERMs): Current roles in the prevention and treatment of osteoporosis

Best Practice and Research: Clinical Rheumatology

Volumn 15, Issue 3, 2001, Pages 451-468

  Albertazzi, P ^a   Purdie, D W ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

HRT; Oestrogen; Osteoporosis; Raloxifene; SERMs

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLOMIFENE; CONJUGATED ESTROGEN; DROLOXIFENE; ENCLOMIFENE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; IDOXIFENE; LEVOMELOXIFENE; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TIBOLONE; TOREMIFENE; UNCLASSIFIED DRUG; ZUCLOMIFENE;

BLEEDING; BONE ATROPHY; BONE REMODELING; BREAST CANCER; BREAST DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTROGEN THERAPY; FRACTURE; HUMAN; LONG TERM CARE; MASTALGIA; MENOPAUSAL SYNDROME; META ANALYSIS; NONHUMAN; PAIN; PATIENT COMPLIANCE; PELVIC ORGAN PROLAPSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STRUCTURE ANALYSIS; VAGINA DISCHARGE;

EID: 0034873477     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2001.0160     Document Type: Article

References (51)

1. The future of ageing
2. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates
3. Morphologic basis of bone mineral measurement: Transient and steady state effects of treatment in osteoporosis
4. Steroid hormone receptor expression and action in bone
5. Cloning of a novel receptor expressed in rat prostate and ovary
6. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
7. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
8. Postmenopausal osteoporosis: How the hormonal changes of menopause cause bone loss
9. Magnitude and pattern of skeletal response to continuous and cyclical sequential oestrogen/progestin treatment
10. Low-dosage micronized 17β-estradiol prevents bone loss on postmenopausal women
11. The effects of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: A randomized controlled trial
12. Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group
13. Postmenopausal bone loss is prevented by treatment with low dosage estrogen with calcium
14. Continuous low dose estrogen and progestogen hormone replacement therapy: A randomized trial
15. Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins
16. Effect of progestin therapy on cortical and trabecular bone; Comparison with estrogen
17. The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous implants
18. The effect of long term oestradial implantation on bone mineral density in postmenopausal women who have undergone hysterectomy and bilateral oophorectomy
19. Tibolone: A review
20. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: A two-year randomised controlled trial
21. Induction of ovulation with MRI-4I
22. Clomiphene protects against osteoporosis in the mature ovariectomized rat
23. Effects of anti-estrogens on bone in castrated and intact female rats
24. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years
25. Selective estrogen receptor modulators: Clinical spectrum
26. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-I study
27. Effect of tamoxifen on the uterus
28. Antiestrogenic properties of raloxifene
29. Molecular basis of agonism and antagonism in the oestrogen receptor
30. Tamoxifen, raloxifen, and the prevention of breast cancer
31. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
32. Structure of the ligand-binding domain of oestrogen receptor beta in the pressence of a partial agonist and full antagonist
33. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonist/antagonist
34. Identification of an oestrogen response element activated by metabolite of 17βestradiol and raloxifen
35. Differential ligand activation of estrogen receptor ERα and ERβ at Ap-I sites
36. Raloxifene and estrogen: Comparative bone-remodeling kinetics
37. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
38. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women
39. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
40. Estrogen replacement therapy and fractures in older women: Study of Osteoporotic Fracture Research Group
41. Decreased risk of fracture of hip and lower forearm with postmenopausal use of estrogen
42. Hormone replacement therapy and the risk for the first hip fracture
43. Maximising the benefit of estrogen therapy for prevention of osteoporosis
44. Estrogen therapy arrests bone loss in elderly women
45. Timing of postmenopausal estrogen for optimal bone mineral density: The Rancho Bernardo Study
46. Progressive loss of bone in the femoral neck in elderly people: Longitudinal findings from Dubbo osteoporosis epidemiology study
47. The effect of raloxifene on risk of breast cancer in postmenopoausal women. Results from the MORE randomized trial
48. Radomized trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
49. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
50. Breast cancer and hormonal replacement tharapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 without breast cancer
51. The economics and management of osteoporosis in postmenopausal women